Lefamulin BC3781, CAS 1061337-51-6

Lefamulin BC3781, CAS 1061337-51-6
Product Details

Lefamulin BC3781, CAS 1061337-51-6, an investigational pleuromutilin, was tested against a collection of 18 macrolide-susceptible and 42 macrolide-resistant Mycoplasma pneumoniae strains in comparison to azithromycin, erythromycin, tetracycline, doxycycline, and moxifloxacin. Lefamulin was highly active against all strains tested, with all MICs ≤ 0.008 μg/ml. The lefamulin MIC90 (0.002 μg/ml) for macrolide-resistant strains was the lowest among all drugs tested. Minimum bactericidal concentrations were within 2 dilutions of the MIC values, indicating a bactericidal effect.

The designation has been granted for lefamulin to treat community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).

Hot Tags: Modafinil, SEX hormones.

Lefamulin BC3781, CAS 1061337-51-6

Related Products

Lefamulin BC3781 (CAS 1061337-51-6) Basic information

Product Name:Lefamulin

Synonyms:Lefamulin;2-[[(1R,2R,4R)-4-Amino-2-hydroxycyclohexyl]thio]acetic acid (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl ester;BC 3781

CAS:1061337-51-6

MF:C28H45NO5S

MW:507.73

LogP:2.90

H Bond Donors: 3

H Bond Acceptors: 5

Rotatable Bonds: 6

Therapeutic Class: Antibiotic, other; Phase III Clinical Trial


Feedback